Related Experiment Videos
Diastolic dysfunction in congestive heart failure
1Department of Clinical Pharmacy, University of Tennessee, Memphis 38163.
Insights
Diastolic dysfunction, a key factor in heart failure with preserved ejection fraction, requires specific therapeutic strategies. Certain medications may help, while others, like digitalis glycosides, could be harmful.
Area of Science:
- Cardiology
- Heart Failure Research
Background:
- Congestive heart failure (CHF) affects millions globally.
- A significant subset of CHF patients exhibit normal systolic function.
- Diastolic dysfunction is increasingly recognized as a primary cause in these patients.
Purpose of the Study:
- To review the evaluation of diastolic function.
- To highlight the significance of diastolic dysfunction in CHF.
- To examine the impact of various therapeutic agents on diastolic dysfunction.
Main Methods:
- Literature review and synthesis.
- Analysis of existing studies on cardiac function and therapeutic interventions.
- Comparison of clinical presentations and treatment responses.
Main Results:
- Diastolic dysfunction underlies 30-40% of CHF cases with normal systolic function.
- Left ventricular hypertrophy and ischemic heart disease are primary causes.
- Clinical presentations of diastolic and systolic dysfunction-induced CHF are similar.
- Diuretics, vasodilators, ACE inhibitors, beta-agonists, and PDE III inhibitors may benefit patients.
- Digitalis glycosides may be detrimental; beta-blockers show neutral effects on diastolic function.
Conclusions:
- Diastolic dysfunction is a critical determinant of CHF.
- Tailored therapeutic approaches are necessary for diastolic dysfunction-related CHF.
- Further research is needed to fully understand diastolic dysfunction and its management.
Abstract:
The available literature on the evaluation of diastolic function, the importance of diastolic dysfunction in congestive heart failure (CHF), and the effects of therapeutic agents on diastolic dysfunction are summarized. The normal cardiac cycle consists of two components: systole (contraction; ventricular emptying) and diastole (dilation; ventricular filling). Recent studies have shown that 30-40% of patients with CHF have normal systolic function; the majority of these patients have diastolic dysfunction as the underlying disorder. As a result, the role of diastolic dysfunction in CHF is currently an area of interest for researchers. The two primary causes of diastolic dysfunction are left ventricular hypertrophy and ischemic heart disease. Patients with CHF caused by diastolic dysfunction and patients with CHF caused by systolic dysfunction have nearly identical clinical presentations. Therapy with diuretics, vasodilators, angiotensin-converting-enzyme inhibitors, beta-agonists, the partial beta-agonist xamoterol, phosphodiesterase III inhibitors, or calcium-channel blockers may be beneficial in patients with diastolic dysfunction. Therapy with digitalis glycosides would be of no benefit, and could theoretically be detrimental, in patients with predominant diastolic dysfunction. Available data indicate that beta blockers have neither an important beneficial effect nor an important detrimental effect on diastolic function. Continued studies into diastolic dysfunction and the diastolic properties of agents that are used in the treatment of CHF should enhance the understanding of this clinical syndrome and the drugs used to treat it.